$Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.$

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Although TP53, NOTCH1, and SF3B1 mutations may impair prognosis of patients with chronic lymphocytic leukemia (CLL) receiving frontline therapy, the impact of these mutations or any other, alone or in combination, remains unclear at relapse. The genome of 114 relapsed/refractory patients included in...

Descripció completa

Dades bibliogràfiques
Autors principals:	Guièze, R, Robbe, P, Clifford, R, de Guibert, S, Pereira, B, Timbs, A, Dilhuydy, M, Cabes, M, Ysebaert, L, Burns, A, Nguyen-Khac, F, Davi, F, Véronèse, L, Combes, P, Le Garff-Tavernier, M, Leblond, V, Merle-Béral, H, Alsolami, R, Hamblin, A, Mason, J, Pettitt, A, Hillmen, P, Taylor, J, Knight, S, Tournilhac, O, Schuh, A
Format:	Journal article
Idioma:	English
Publicat:	American Society of Hematology 2015

Ítems similars

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
per: Hillmen, P, et al.
Publicat: (2006)

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
per: Anne Quinquenel, et al.
Publicat: (2020-10-01)

Clinical‐grade validation of whole genome sequencing reveals robust detection of low‐frequency variants and copy number alterations in CLL
per: Klintman, J, et al.
Publicat: (2018)

UK experience of Ofatumumab in refractory B-CLL
per: Varghese, A, et al.
Publicat: (2011)

Identification of Novel Recurrent Copy Number Variations and Regions of Copy-Neutral Loss of Heterozygosity by High Resolution Genomic Array in Pre-Treatment and Relapsed B-CLL.
per: Knight, S, et al.
Publicat: (2009)

The CLL hunters: finally, BTK got arrested
per: Loic Ysebaert
Publicat: (2025-01-01)

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial.
per: Catovsky, D, et al.
Publicat: (2006)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
per: Catovsky, D, et al.
Publicat: (2004)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
per: Hillmen, P, et al.
Publicat: (2005)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
per: Catovsky, D, et al.
Publicat: (2007)

Early results from LRF CLL4: A UK multicenter randomized trial
per: Catovsky, D, et al.
Publicat: (2005)

Experiences in the design and implementation of phase II trials in CLL
per: Cohen Dena R, et al.
Publicat: (2011-12-01)

P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY
per: Loïc Ysebaert, et al.
Publicat: (2023-08-01)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
per: Munir, T, et al.
Publicat: (2014)

Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.
per: Osterborg, A, et al.
Publicat: (2012)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
per: Catovsky, D, et al.
Publicat: (2006)

Prognostic factors in the UK LRF CLL4 trial
per: Oscier, D, et al.
Publicat: (2006)

Prognostic factors in the UK LRF CLL4 trial.
per: Oscier, D, et al.
Publicat: (2005)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
per: Dearden, C, et al.
Publicat: (2011)

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
per: Pettitt, A, et al.
Publicat: (2012)

P672: REAL-LIFE EFFICACY AND SAFETY OF VENETOCLAX MONOTHERAPY IN RELAPSED/ REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA - INTERIM ANALYSIS OF MULTICENTRIC STUDY VERONE
per: L. Ysebaert, et al.
Publicat: (2022-06-01)

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)
per: Hillmen, P, et al.
Publicat: (2014)

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
per: Burns, A, et al.
Publicat: (2017)

The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia
per: Magali Le Garff-Tavernier, et al.
Publicat: (2015-04-01)

REAL-WORLD ANALYSIS OF PATIENTS WITH CLL TREATED WITH IBRUTINIB: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN REGISTRY OF CLL
per: V Pfister, et al.
Publicat: (2024-10-01)

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
per: Richard Lemal, et al.
Publicat: (2022-05-01)

A Multi-Reconfigurable CLL-Loaded Planar Monopole Antenna
per: M. M. Fakharian, et al.
Publicat: (2020-06-01)

Preliminary results of the UK Medical Research Council trial in chronic lymphocytic leukaemia - CLL3
per: Catovsky, D, et al.
Publicat: (1998)

Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)
per: McClanahan, F, et al.
Publicat: (2010)

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
per: Else, M, et al.
Publicat: (2006)

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
per: P. Hillmen, et al.
Publicat: (2022-06-01)

Targeting Bruton’s Tyrosine Kinase in CLL
per: Inhye E. Ahn, et al.
Publicat: (2021-06-01)

UK Medical Research Council CLL3 - A randomized trial of the addition of epirubicin to standard chlorambucil treatment.
per: Catovsky, D, et al.
Publicat: (2000)

Glabellar and auricular leukemia cutis in CLL
per: Bradley Steinman, et al.
Publicat: (2022-11-01)

P599: RARE GERMLINE VARIANTS IN ATM INFLUENCE THE PATHOGENESIS OF CLL
per: B. L. Lampson, et al.
Publicat: (2022-06-01)

IGHV Mutational Status in a Cohort of Bulgarian CLL Patients: High Unmutated CLL Prevalence in North-East Bulgaria
per: Yosifova A, et al.
Publicat: (2024-09-01)

Quantitative Whole Genome Analysis of Sequential Samples From Patients with B-CLL Identifies Novel Recurrent Copy Number Alterations Involving Critical B-Cell Transcription Factors
per: Timbs, A, et al.
Publicat: (2010)

Quantitative Whole Genome Analysis of Sequential Samples From Patients with B CLL Identifies Novel Recurrent Copy Number Alterations Involving Critical B Cell Transcription Factors
per: Timbs, A, et al.
Publicat: (2010)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial
per: Andrew R. Pettitt, et al.
Publicat: (2020-02-01)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
per: Yucai Wang, et al.
Publicat: (2021-08-01)